(Q38107303)

29 August 2017

title

Prognosis and monitoring of leishmaniasis in dogs: a working group report (English)

1 reference

29 August 2017

4

Luigi Gradoni

1 reference

29 August 2017

Xavier Roura

1

1 reference

29 August 2017

Alessandra Fondati

2

1 reference

29 August 2017

George Lubas

3

1 reference

29 August 2017

Michele Maroli

5

1 reference

29 August 2017

Gaetano Oliva

6

1 reference

29 August 2017

Saverio Paltrinieri

7

1 reference

29 August 2017

Andrea Zatelli

8

1 reference

29 August 2017

Eric Zini

9

1 reference

29 August 2017

publication date

14 May 2013

1 reference

29 August 2017

published in

The Veterinary Journal

1 reference

29 August 2017

volume

198

1 reference

29 August 2017

issue

1

1 reference

29 August 2017

page(s)

43-47

1 reference

Changes in antibody titres against Leishmania infantum in naturally infected dogs in southern Spain.

29 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2013.04.001

Canine leishmaniasis: clinical, parasitological and entomological follow-up after chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2013.04.001

Perspective-- FcRn transports albumin: relevance to immunology and medicine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2013.04.001

Canine leishmaniosis - new concepts and insights on an expanding zoonosis: part one.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2013.04.001

Canine visceral leishmaniasis: relationships between clinical status, humoral immune response, haematology and Lutzomyia (Lutzomyia) longipalpis infectivity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2013.04.001

Associations among immunological, parasitological and clinical parameters in canine visceral leishmaniasis: Emaciation, spleen parasitism, specific antibodies and leishmanin skin test reaction.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2013.04.001

Serological diagnosis and treatment of canine leishmaniasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2013.04.001

Progression of chronic renal disease in the dog.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2013.04.001

Advantages of real-time PCR assay for diagnosis and monitoring of canine leishmaniosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2013.04.001

Clinical considerations on canine visceral leishmaniasis in Greece: a retrospective study of 158 cases (1989-1996)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2013.04.001

Studies on canine leishmaniasis control. 1. Evolution of infection of different clinical forms of canine leishmaniasis following antimonial treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2013.04.001

Leishmania DNA load and cytokine expression levels in asymptomatic naturally infected dogs.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2013.04.001

Leishmania DNA quantification by real-time PCR in naturally infected dogs treated with miltefosine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2013.04.001

Guidelines for prevention of leishmaniasis in dogs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2013.04.001

Canine leishmaniasis: the key points for qPCR result interpretation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2013.04.001

Serum concentrations of acute-phase proteins in dogs with leishmaniosis during short-term treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2013.04.001

Acute phase protein response in experimental canine leishmaniosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2013.04.001

Characterization of circulating lymphocyte subpopulations in canine leishmaniasis throughout treatment with antimonials and allopurinol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2013.04.001

Characterization of sex, age, and breed for a population of canine leishmaniosis diseased dogs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2013.04.001

Multicentric, controlled clinical study to evaluate effectiveness and safety of miltefosine and allopurinol for canine leishmaniosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2013.04.001

Infectivity to Phlebotomus perniciosus of dogs naturally parasitized with Leishmania infantum after different treatments.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2013.04.001

Treatment of canine Old World visceral leishmaniasis: a systematic review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2013.04.001

Incidence and time course of Leishmania infantum infections examined by parasitological, serologic, and nested-PCR techniques in a cohort of naive dogs exposed to three consecutive transmission seasons

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2013.04.001

Guidelines for treatment of leishmaniasis in dogs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2013.04.001

Toward diagnosing Leishmania infantum infection in asymptomatic dogs in an area where leishmaniasis is endemic

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2013.04.001

Guidelines for diagnosis and clinical classification of leishmaniasis in dogs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2013.04.001

Clinical and laboratory monitoring of dogs naturally infected by Leishmania infantum.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2013.04.001

Monitoring the reverse to normal of clinico-pathological findings and the disease free interval time using four different treatment protocols for canine leishmaniosis in an endemic area

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2013.04.001

Effects of allopurinol treatment on the progression of chronic nephritis in Canine leishmaniosis (Leishmania infantum)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2013.04.001

Genetic control of canine leishmaniasis: genome-wide association study and genomic selection analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2013.04.001

Systemic and compartmentalized immune response in canine visceral leishmaniasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2013.04.001

Dynamics of Leishmania-specific immunoglobulin isotypes in dogs with clinical leishmaniasis before and after treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2013.04.001

One-year clinical and parasitological follow-up of dogs treated with marbofloxacin for canine leishmaniosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2013.04.001

Canine leishmaniasis. A review based on 95 cases in The Netherlands

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2013.04.001

The effect of intravenous or subcutaneous administration of meglumine antimonate (Glucantime) in dogs with leishmaniasis. A randomized clinical trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2013.04.001

The Ibizian hound presents a predominantly cellular immune response against natural Leishmania infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2013.04.001

Leishmania infantum-specific IgG, IgG1 and IgG2 antibody responses in healthy and ill dogs from endemic areas. Evolution in the course of infection and after treatment.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2013.04.001

Directions for the diagnosis, clinical staging, treatment and prevention of canine leishmaniosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2013.04.001

LeishVet guidelines for the practical management of canine leishmaniosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2013.04.001

Long term follow-up of dogs diagnosed with leishmaniosis (clinical stage II) and treated with meglumine antimoniate and allopurinol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2013.04.001

Transmission potential, skin inflammatory response, and parasitism of symptomatic and asymptomatic dogs with visceral leishmaniasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2013.04.001

10.1016/J.TVJL.2013.04.001

7 January 2021

Identifiers

DOI

1 reference

29 August 2017

1 reference